Organization
Albireo
Aliases
Albireo, an Ipsen Company
14 clinical trials
Clinical trial
Odevixibat (A4250) for the Treatment of Progressive Familial Intrahepatic Cholestasis (Expanded Access Program)Status:
Clinical trial
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
Phase 1, Open-Label, Randomized, 3-Way Crossover Relative Bioavailability of A4250 in Healthy Adult Subjects Under Fasting and Fed Conditions and When Sprinkled on ApplesauceStatus: Completed, Estimated PCD: 2018-08-05
Clinical trial
A Phase II, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of A3384 in Patients With Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)Status: Completed, Estimated PCD: 2014-12-01
Clinical trial
A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With DyslipidemiaStatus: Completed, Estimated PCD: 2010-09-01
Clinical trial
An Exploratory Phase II Study to Demonstrate the Safety and Efficacy of A4250 in Children With Cholestatic PruritusStatus: Completed, Estimated PCD: 2017-03-17
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai HepatoportoenterostomyStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT)Status: Active (not recruiting), Estimated PCD: 2024-02-07
Clinical trial
An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults With Primary Sclerosing Cholangitis (PSC)Status: Recruiting, Estimated PCD: 2025-06-14
Clinical trial
An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male SubjectsStatus: Completed, Estimated PCD: 2017-03-08
Clinical trial
A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy SubjectsStatus: Completed, Estimated PCD: 2014-05-01
Clinical trial
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia (BOLD-EXT)Status: , Estimated PCD: 2024-12-31
Clinical trial
A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)Status: Completed, Estimated PCD: 2022-09-09
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai HepatoportoenterostomyStatus: Active (not recruiting), Estimated PCD: 2026-06-30